Intra-Cellular Therapies Inc ITCI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ITCI is a good fit for your portfolio.
News
-
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
-
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
-
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
-
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
-
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Intra-Cellular Therapies Prices Public Offering of Common Stock
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Trading Information
- Previous Close Price
- $65.65
- Day Range
- $65.81–67.70
- 52-Week Range
- $45.50–84.89
- Bid/Ask
- $64.01 / $70.74
- Market Cap
- $7.10 Bil
- Volume/Avg
- 1.0 Mil / 942,588
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 561
Comparables
Valuation
Metric
|
ITCI
|
MRNS
|
SMMT
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.82 | — | 46.60 |
Price/Sales | 12.51 | 2.76 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ITCI
MRNS
SMMT
Financial Strength
Metric
|
ITCI
|
MRNS
|
SMMT
|
---|---|---|---|
Quick Ratio | 4.50 | 2.73 | 6.73 |
Current Ratio | 5.12 | 3.07 | 6.97 |
Interest Coverage | — | −8.02 | −10.03 |
Quick Ratio
ITCI
MRNS
SMMT
Profitability
Metric
|
ITCI
|
MRNS
|
SMMT
|
---|---|---|---|
Return on Assets (Normalized) | −9.15% | −59.45% | −43.80% |
Return on Equity (Normalized) | −10.98% | −195.80% | −100.68% |
Return on Invested Capital (Normalized) | −13.47% | −84.00% | −45.83% |
Return on Assets
ITCI
MRNS
SMMT
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Rywnwybnkv | Bvffn | $78.4 Bil | |
ZTS
| Zoetis Inc Class A | Pdkdsclj | Jzq | $77.9 Bil | |
HLN
| Haleon PLC ADR | Skwckfqdq | Zmc | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Mhjwdxcj | Msm | $18.8 Bil | |
VTRS
| Viatris Inc | Ckcqsmtz | Pkv | $12.5 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Bmbnczd | Jntq | $12.0 Bil | |
CTLT
| Catalent Inc | Kskhygjh | Mqrxs | $9.7 Bil | |
PRGO
| Perrigo Co PLC | Xbxrgzmjz | Fknw | $3.7 Bil | |
CURLF
| Curaleaf Holdings Inc | Bqpcgyq | Djrf | $3.4 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Qkdrnhhsx | Htprqx | $3.1 Bil |